Ubs Group Ag Immunovant, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Immunovant, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 202,550 shares of IMVT stock, worth $5.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

202,550

Previous 155,082 30.61%

Holding current value

$5.57 Million

Previous $6.53 Million 0.17%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$30.27 - $43.79 $1.44 Million - $2.08 Million	47,468 Added 30.61%	202,550 $6.54 Million
Q4 2023 Feb 09, 2024	BUY	$31.31 - $44.19 $2.2 Million - $3.11 Million	70,285 Added 82.89%	155,082 $6.53 Million
Q3 2023 Nov 09, 2023	SELL	$18.55 - $39.96 $132,409 - $285,234	-7,138 Reduced 7.76%	84,797 $3.26 Million
Q2 2023 Aug 11, 2023	SELL	$14.2 - $23.75 $441,634 - $738,648	-31,101 Reduced 25.28%	91,935 $1.74 Million
Q1 2023 May 12, 2023	SELL	$15.27 - $19.72 $470,911 - $608,145	-30,839 Reduced 20.04%	123,036 $1.91 Million

Q4 2022 Feb 08, 2023	BUY	$6.59 - $17.75 $968,051 - $2.61 Million	146,897 Added 2105.14%	153,875 $2.73 Million
Q3 2022 Nov 10, 2022	BUY	$3.93 - $6.37 $18,451 - $29,907	4,695 Added 205.65%	6,978 $39,000
Q2 2022 Aug 10, 2022	BUY	$3.38 - $5.65 $7,716 - $12,898	2,283 New	2,283 $9,000
Q1 2022 May 16, 2022	SELL	$5.06 - $8.77 $842,662 - $1.46 Million	-166,534 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $863,444 - $1.1 Million	117,796 Added 241.69%	166,534 $1.42 Million
Q3 2021 Nov 15, 2021	BUY	$7.01 - $11.37 $84,785 - $137,520	12,095 Added 33.01%	48,738 $423,000
Q2 2021 Aug 13, 2021	SELL	$9.4 - $16.85 $436,977 - $783,305	-46,487 Reduced 55.92%	36,643 $387,000
Q1 2021 May 12, 2021	BUY	$13.08 - $49.6 $443,346 - $1.68 Million	33,895 Added 68.84%	83,130 $1.33 Million
Q4 2020 Feb 11, 2021	BUY	$36.36 - $52.71 $1.76 Million - $2.55 Million	48,396 Added 5768.3%	49,235 $2.27 Million
Q3 2020 Nov 12, 2020	SELL	$22.61 - $38.9 $138,282 - $237,912	-6,116 Reduced 87.94%	839 $30,000
Q2 2020 Jul 31, 2020	BUY	$13.87 - $28.44 $63,774 - $130,767	4,598 Added 195.08%	6,955 $169,000
Q1 2020 May 01, 2020	BUY	$8.36 - $17.13 $10,709 - $21,943	1,281 Added 119.05%	2,357 $37,000
Q4 2019 Feb 14, 2020	BUY	$10.02 - $16.4 $10,781 - $17,646	1,076 New	1,076 $17,000

Others Institutions Holding IMVT

# of Institutions

238

Shares Held

62.9M

Call Options Held

1.46M

Put Options Held

546K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account